Catherine Alix-Panabières/umontpellier.fr
Mar 20, 2025, 10:42
Catherine Alix-Panabières: New Insights into Circulating Tumor Cells in Metastatic Breast Cancer
Catherine Alix-Panabières, Professor of Oncology at the Faculty of Medicine of the University of Montpellier, shared an article by Wolfgang Janni, et al. on LinkedIn:
“New Insights into Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer!
The PREDICT study, analyzing 4,436 patients, confirms that serial CTC assessments are powerful predictors of overall survival (OS) in metastatic breast cancer (MBC)—across all subtypes and treatments.
Key findings:
- Patients with persistently low CTCs (neg/neg) had the best OS (45.6 months).
- CTC non-responders (pos/pos) had the worst OS (17.3 months).
- CTC responders (pos/neg) showed a 52% lower risk of death vs. non-responders.
Why it matters?
These findings reinforce the need for CTC monitoring as a tool for risk stratification and early treatment response assessment in MBC. New randomized trials are crucial to define its clinical utility.
Good reading.”
Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis.
Authors: Wolfgang Janni, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 20, 2025, 11:30
Mar 20, 2025, 11:18
Mar 20, 2025, 11:01
Mar 20, 2025, 10:35
Mar 20, 2025, 10:23